Population pharmacokinetics of oxcarbazepine: a systematic review

References

• Schwabe S. Oxcarbazepine: clinical development program. Epilepsia. 1994;35(Suppl 5):S51–3.
   PubMedGoogle Scholar
• Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs. 2001;15(2):137–163.
   PubMed Web of Science ®Google Scholar
• Schachter SC. Oxcarbazepine: current status and clinical applications. Expert Opin Investig Drugs. 1999 Jul;8(7):1103–1112.
   PubMedGoogle Scholar
• Maiti R, Mishra BR, Sanyal S, et al. Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: a randomized controlled trial. Epilepsy Res. 2017 Dec;138:5–10.
   PubMed Web of Science ®Google Scholar
• Schütz H, Feldmann KF, Faigle JW, et al. The metabolism of 14C-oxcarbazepine in man. Xenobiotica. 1986 Aug;16(8):769–778.
   PubMed Web of Science ®Google Scholar
• May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023–1042.
   PubMed Web of Science ®Google Scholar
• Di Girolamo G, Opezzo JA, Schere D, et al. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers? Expert Opin Pharmacother. 2007 Jul;8(10):1415–1423.
   PubMed Web of Science ®Google Scholar
• Lu Y, Fang Y, Wu X, et al. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol. 2017 Mar;73(3):307–315.
   PubMed Web of Science ®Google Scholar
• Van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther. 1991 Oct;50(4):410–419.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol. 1990;39(4):413–415.
   PubMed Web of Science ®Google Scholar
• Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig. 2004;24(4):185–203.
   PubMed Web of Science ®Google Scholar
• Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol. 1994;47(2):161–167.
   PubMed Web of Science ®Google Scholar
• Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001 Sep 11;57(5):864–871.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Lattanzi S, Brigo F, et al. Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice. Epilepsy Behav. 2020 Mar;104(Pt A):106939.
   PubMedGoogle Scholar
• Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet. 2008;47(12):767–778.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972 Oct;5(5):411–459.
   PubMedGoogle Scholar
• Sasaki T, Tabuchi H, Higuchi S, et al. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics. 2009 Aug;10(8):1257–1266.
   PubMed Web of Science ®Google Scholar
• Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical Pharmacokinetic Studies: the ClinPK Statement. Clin Pharmacokinet. 2015 Jul;54(7):783–795.
   PubMed Web of Science ®Google Scholar
• Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokinetic-pharmacodynamic study: a journal’s perspective. Clin Pharmacokinet. 2014 Feb;53(2):111–122.
   PubMed Web of Science ®Google Scholar
• Burns DR, Elswick RK. Equivalence testing with dental clinical trials. J Dent Res. 2001 Jun;80(6):1513–1517.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Curr Med Res Opin. 2005 Sep;21(9):1363–1368.
   PubMed Web of Science ®Google Scholar
• Ling J, Lx Q, Jj D, et al. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters]. Yao Xue Xue Bao. 2014 May;49(5):686–694.
   PubMedGoogle Scholar
• Liu M, Ma CL, Jiao Z. et al. Population pharmacokinetics of oxcarbazepine in Chinese epilepsy patients [Article]. Yaoxue Xuebao. 2018;53(8):1318–1323.
   Google Scholar
• Sallas WM, Milosavljev S, D’Souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther. 2003 Aug;74(2):138–149.
   PubMed Web of Science ®Google Scholar
• Sugiyama I, Bouillon T, Yamaguchi M, et al. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet. 2015 Apr;30(2):160–167.
   PubMed Web of Science ®Google Scholar
• Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol. 2005 Nov;33(5):337–344.
   PubMed Web of Science ®Google Scholar
• Park KJ, Kim JR, Joo EY, et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol. 2012 Jan-Feb;35(1):40–44.
   PubMed Web of Science ®Google Scholar
• Peng J, Zhang HN, Liu ZS, et al. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin Pharmacol Ther. 2014 Aug;52(8):684–692.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang HN, Niu CH, et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin. 2014 Oct;35(10):1342–1350.
   PubMed Web of Science ®Google Scholar
• Lin WW, Wang CL, Jiao Z, et al. Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: a Population Pharmacokinetic Analysis. Ther Drug Monit. 2019 Oct;41(5):665–673.
   PubMed Web of Science ®Google Scholar
• Lin WW, Li XW, Jiao Z, et al. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2019 Mar;75(3):381–392.
   PubMed Web of Science ®Google Scholar
• Chen CY, Zhou Y, Cui YM, et al. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther. 2019 Apr;44(2):300–311.
   PubMed Web of Science ®Google Scholar
• Rodrigues C, Chiron C, Rey E, et al. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol. 2017 Dec;83(12):2695–2708.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang Q, Xu W, et al. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):345–351.
   PubMed Web of Science ®Google Scholar
• Antunes NJ, Van Dijkman SC, Lanchote VL, et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci. 2017;15:109s:S116–s123.
   Google Scholar
• Wegner I, Edelbroek P, De Haan GJ, et al. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia. 2010 Dec;51(12):2500–2502.
   PubMed Web of Science ®Google Scholar
• Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008 May;90(2):154–166.
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45(4):351–363.
   PubMed Web of Science ®Google Scholar
• Choonara IA, McKay P, Hain R, et al. Morphine metabolism in children. Br J Clin Pharmacol. 1989 Nov;28(5):599–604.
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999 Jun;36(6):439–452.
   PubMed Web of Science ®Google Scholar
• Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005 Nov 8;65(9):1370–1375.
   PubMed Web of Science ®Google Scholar
• Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia. 1994;35(Suppl 3):S14–9.
   PubMedGoogle Scholar
• McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994 Jan;37(1):27–32.
   PubMed Web of Science ®Google Scholar
• Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharm Drug Dispos. 1990 May-Jun;11(4):365–370.
   PubMed Web of Science ®Google Scholar
• French JA, Baroldi P, Brittain ST, et al. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand. 2014 Mar;129(3):143–153.
   PubMed Web of Science ®Google Scholar
• Verscheijden LFM, Koenderink JB, Johnson TN, et al. Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther. 2020 Jul;211:107541.
   PubMed Web of Science ®Google Scholar
• Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol. 2017 Feb;83(2):247–254.
   PubMed Web of Science ®Google Scholar
• Mehrotra N, Bhattaram A, Earp JC, et al. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling. Drug Metab Dispos. 2016 Jul;44(7):924–933.
   PubMed Web of Science ®Google Scholar